190 related articles for article (PubMed ID: 37481818)
1. Relationship of tryptophan metabolites with the type and severity of multiple sclerosis.
Isık SMT; Onmaz DE; Ekmekci AH; Ozturk S; Unlu A; Abusoglu S
Mult Scler Relat Disord; 2023 Sep; 77():104898. PubMed ID: 37481818
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
[TBL] [Abstract][Full Text] [Related]
4. A review of chromatographic methods for bioactive tryptophan metabolites, kynurenine, kynurenic acid, quinolinic acid, and others, in biological fluids.
Fukushima T; Umino M; Sakamoto T; Onozato M
Biomed Chromatogr; 2022 May; 36(5):e5308. PubMed ID: 34978092
[TBL] [Abstract][Full Text] [Related]
5. Development of a translational inflammation panel for the quantification of cerebrospinal fluid Pterin, Tryptophan-Kynurenine and Nitric oxide pathway metabolites.
Yan J; Han VX; Heng B; Guillemin GJ; Bandodkar S; Dale RC
EBioMedicine; 2022 Mar; 77():103917. PubMed ID: 35279631
[TBL] [Abstract][Full Text] [Related]
6. Abnormal Activation of Tryptophan-Kynurenine Pathway in Women With Polycystic Ovary Syndrome.
Wang S; Mu L; Zhang C; Long X; Zhang Y; Li R; Zhao Y; Qiao J
Front Endocrinol (Lausanne); 2022; 13():877807. PubMed ID: 35721725
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases.
Mangoni AA; Zinellu A
Front Immunol; 2023; 14():1257159. PubMed ID: 37936702
[TBL] [Abstract][Full Text] [Related]
8. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
9. Altered serum levels of kynurenine metabolites in patients affected by cluster headache.
Curto M; Lionetto L; Negro A; Capi M; Perugino F; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17(1):27. PubMed ID: 27000870
[TBL] [Abstract][Full Text] [Related]
10. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.
Myint AM; Schwarz MJ; Verkerk R; Mueller HH; Zach J; Scharpé S; Steinbusch HW; Leonard BE; Kim YK
Brain Behav Immun; 2011 Nov; 25(8):1576-81. PubMed ID: 21620952
[TBL] [Abstract][Full Text] [Related]
11. A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis.
Tömösi F; Kecskeméti G; Cseh EK; Szabó E; Rajda C; Kormány R; Szabó Z; Vécsei L; Janáky T
J Pharm Biomed Anal; 2020 Jun; 185():113246. PubMed ID: 32182446
[TBL] [Abstract][Full Text] [Related]
12. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.
Brum M; Nieberler M; Kehrwald C; Knopf K; Brunkhorst-Kanaan N; Etyemez S; Allers KA; Bittner RA; Slattery DA; McNeill RV; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2023; 24(7):564-577. PubMed ID: 36648064
[TBL] [Abstract][Full Text] [Related]
13. Changes in Tryptophan Metabolism on Serotonin and Kynurenine Pathways in Patients with Irritable Bowel Syndrome.
Chojnacki C; Błońska A; Konrad P; Chojnacki M; Podogrocki M; Poplawski T
Nutrients; 2023 Mar; 15(5):. PubMed ID: 36904262
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
[TBL] [Abstract][Full Text] [Related]
15. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
16. Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Curto M; Lionetto L; Negro A; Capi M; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17():47. PubMed ID: 27130315
[TBL] [Abstract][Full Text] [Related]
17. A validated liquid chromatography-high resolution-tandem mass spectrometry method for the simultaneous quantitation of tryptophan, kynurenine, kynurenic acid, and quinolinic acid in human plasma.
Arnhard K; Pitterl F; Sperner-Unterweger B; Fuchs D; Koal T; Oberacher H
Electrophoresis; 2018 May; 39(9-10):1171-1180. PubMed ID: 29327354
[TBL] [Abstract][Full Text] [Related]
18. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
19. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Sun Y; Drevets W; Turecki G; Li QS
Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
Badawy AA
Med Hypotheses; 2018 Sep; 118():129-138. PubMed ID: 30037600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
